Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly FCF Margin came in at 1257.09% in Q1 2026, down 34974.0% YoY from N/an in Q1 2025, and down 993.68% on a QoQ basis from 114.94% in Q4 2025.
Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of FCF Margin data on file, last reported at 1257.09% in Q1 2026.
- Quarterly FCF Margin fell 34974.0% year-over-year to 1257.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 480.93% (up 18424.0% YoY) and the FY2025 annual result came in at 497.86%, up 13585.0% from the prior year.
- FCF Margin eased to 1257.09% in Q1 2026, from 114.94% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1369.7% in Q1 2022 to a low of 2567.71% in Q4 2024.
- A 5-year average of 707.72% and a median of 646.87% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 259765 bps — and 2025, when it tumbled 209121 bps.
- Tracing RXRX's FCF Margin over 5 years: stood at 308.91% in 2022, then sank by 156 bps to 789.94% in 2023, then tumbled by 225 bps to 2567.71% in 2024, then soared by 96 bps to 114.94% in 2025, then slumped by 994 bps to 1257.09% in 2026.
- The last three FCF Margin figures came in at 1257.09% (Q1 2026), 114.94% (Q4 2025), and 2363.71% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -1,381.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,381.89% |
| Mar 31, 2026 | -1,257.09% |
| Dec 31, 2025 | -114.94% |
| Sep 30, 2025 | -2,363.71% |
| Jun 30, 2025 | -389.37% |
| Mar 31, 2025 | -907.35% |
| Dec 31, 2024 | -2,567.71% |
| Sep 30, 2024 | -272.50% |
| Jun 30, 2024 | -527.95% |
| Mar 31, 2024 | -789.86% |
| Dec 31, 2023 | -789.94% |
| Sep 30, 2023 | -692.24% |
| Jun 30, 2023 | -565.47% |
| Mar 31, 2023 | -646.87% |
| Dec 31, 2022 | -308.91% |
| Sep 30, 2022 | -406.23% |
| Jun 30, 2022 | -800.82% |
| Mar 31, 2022 | 1,369.70% |
| Dec 31, 2021 | -2,590.68% |
| Sep 30, 2021 | -1,687.21% |